We are live on
!
Find out more
BBA
Baker Bros. Advisors Portfolio holdings
AUM
$17.4B
1-Year Est. Return
131.5%
This Fund
S&P 500
This Quarter
Est. Return
+2.27%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.4B
AUM Growth
+$337M
(+2%)
Cap. Flow
+$511M
Cap. Flow
% of AUM
2.93%
Top 10 Holdings %
Top 10 Hldgs %
73.49%
Holding
93
New
8
Increased
18
Reduced
6
Closed
9
Top Buys
| 1 |
Praxis Precision Medicines
PRAX
|
+$194M |
| 2 |
GRAL
GRAIL Inc
GRAL
|
+$151M |
| 3 |
Insmed
INSM
|
+$127M |
| 4 |
Mirum Pharmaceuticals
MIRM
|
+$42M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$31.4M |
Top Sells
| 1 |
Ultragenyx Pharmaceutical
RARE
|
+$63.8M |
| 2 |
Immunocore
IMCR
|
+$51.4M |
| 3 |
TERN
Terns Pharmaceuticals
TERN
|
+$38.4M |
| 4 |
BioNTech
BNTX
|
+$25.6M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$22M |
Sector Composition
| 1 | Healthcare | 99.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Crinetics Pharmaceuticals
CRNX
$8.86B
| $85.4M | 0.49% |
2,351,465
+702,596
| +43% | +$31.4M |
|
27
Replimune Group
REPL
$836M
| $84.5M | 0.49% |
11,045,336
| – | – |
|
28
Nurix Therapeutics
NRIX
$2.4B
| $72.2M | 0.41% |
4,658,556
| – | – |
|
29
Denali Therapeutics
DNLI
$3.6B
| $71.6M | 0.41% |
3,731,695
| – | – |
|
30
Dianthus Therapeutics
DNTH
$5.51B
| $71.5M | 0.41% |
852,164
+62,405
| +8% | +$3.61M |
|
31
Monte Rosa Therapeutics
GLUE
$1.97B
| $71.5M | 0.41% |
4,345,736
| – | – |
|
32
Structure Therapeutics
GPCR
$3.62B
| $69M | 0.4% |
1,432,529
| – | – |
|
33
Entrada Therapeutics
TRDA
$254M
| $64M | 0.37% |
5,072,730
| – | – |
|
|
BCYC
34
Bicycle Therapeutics
BCYC
$299M
| $50.5M | 0.29% |
10,885,357
| – | – |
|
35
Spyre Therapeutics
SYRE
$8.96B
| $50.4M | 0.29% |
1,000,000
| – | – |
|
|
RAPP
36
Rapport Therapeutics
RAPP
$1.98B
| $48.4M | 0.28% |
1,547,090
| – | – |
|
|
ALMS
37
Alumis Inc
ALMS
$3.51B
| $44.3M | 0.25% |
2,012,500
+450,000
| +29% | +$11.2M |
|
|
38
Mirum Pharmaceuticals
MIRM
$7.34B
| $41.2M | 0.24% |
+445,975
| New | +$42M |
|
39
Viridian Therapeutics
VRDN
$2.12B
| $38.6M | 0.22% |
1,971,678
| – | – |
|
40
Enliven Therapeutics
ELVN
$3.68B
| $35.5M | 0.2% |
905,191
+633,785
| +234% | +$17.6M |
|
41
Prelude Therapeutics
PRLD
$355M
| $34.6M | 0.2% |
10,123,824
| – | – |
|
|
DBVT
42
DBV Technologies
DBVT
$962M
| $30.5M | 0.18% |
1,461,425
| – | – |
|
43
Design Therapeutics
DSGN
$883M
| $27.5M | 0.16% |
2,585,978
+352,879
| +16% | +$3.57M |
|
|
CNTA
44
DELISTED
Centessa Pharmaceuticals
CNTA
| $26.6M | 0.15% |
670,751
| – | – |
|
45
CytomX Therapeutics
CTMX
$816M
| $23.4M | 0.13% |
4,975,826
+725,000
| +17% | +$3.68M |
|
|
JBIO
46
Jade Biosciences
JBIO
$1.3B
| $23.1M | 0.13% |
1,641,137
| – | – |
|
47
Disc Medicine
IRON
$2.85B
| $22.4M | 0.13% |
349,657
+12,607
| +4% | +$875K |
|
|
48
Immunocore
IMCR
$1.73B
| $22.1M | 0.13% |
734,397
-1,588,259
| -68% | -$51.4M |
|
49
Xenon Pharmaceuticals
XENE
$6.54B
| $21.5M | 0.12% |
370,208
| – | – |
|
50
Celldex Therapeutics
CLDX
$3.03B
| $21.1M | 0.12% |
665,370
| – | – |
|
Similar funds
MCM
ASRS
PP
CS
SFA
VMPIC
LA
BCIM